Abstract. Up-regulation of phosphatidylinositol-3-kinase (PI3K)-AKT signaling facilitates tumor cell growth and inhibits cell demise. The AKT-pathway also plays an important role in cytostatic therapy resistance and response to hypoxia and angiogenesis. Using real-time cell proliferation assay we examined the potency of triciribine in three distinct neuroendocrine gastrointestinal tumor cell lines. Also we investigated triciribine's induction of apoptosis and effects on a broad range of cancer-associated gene products. Furthermore, we characterized the role of PTEN as a possible predictor of sensitivity to triciribine in GEP-NETs. We also looked for additive anti-neoplastic effects of triciribine when combined with conventional cytostatic drugs or other targeted drugs, affecting different molecules of the PI3K-AKT-pathway and we assessed the potency of triciribine to inhibit tumor growth in vivo, by using the chick chorioallantoic membrane assay. Treatment of insulinoma (CM) or gut neuroendocrine tumor cells (STC-1) with triciribine significantly reduced tumor cell growth by 59% and 65%, respectively. By contrast, the highly expressing PTEN carcinoid cell line BON did not respond, even at higher doses. Combinations of triciribine with classic cytostatic drugs as well as drugs targeting other molecules of the PI3K-AKT-pathway led to synergistic anti-proliferative effects. Additional in vivoevaluations confirmed the anti-neoplastic potency of triciribine. Thus, our data show that inhibition the AKT-pathway potently reduces the growth of GEP-NET cells alone or in combination therapies. AKT inhibition may provide a rationale for future evaluations.
Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), often synonymously called carcinoids, are a very heterogeneous group of neoplasms. Originally thought of as representing a rather homogeneous group, advances in the knowledge of molecular changes within different tumor entities of the GEP-NETs led to the classification system of the WHO in 2000 (1), later supplemented with additional studies (2) .
With a reported incidence of 2-3:100,000 GEP-NETs are relatively rare, but the 5-year survival rate is only about 67% (3, 4) . For localized tumors, systemic symptoms can be absent, since often its products, excess biogenic amines and hormones, are mostly cleared by the liver. Metastasized tumors, however, have often incapacitating symptoms, e.g., for the carcinoid syndrome including diarrhea, flushing, wheezing and skin rashes.
The treatment of choice in locally defined tumors is still surgical resection (5) . However, at presentation, about 80% of patients have already developed liver or lymph node metastases. In the advanced stages, the medical treatment options are still poor. Currently, different chemotherapeutic regimens are used, depending amongst others on the differentiation of the tumor, including etoposide plus cisplatin or streptozotocin with 5-FU or doxorubicin (6) (7) (8) . However, response rates of 0-30% are still disappointing. In well-differentiated tumors, somatostatin-analogues (lanreotide, octreotide) have been shown to be effective not only in controlling side effects caused by hormone secretion but also in controlling tumor growth (9) .
The phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway has been introduced as an attractive target for cancer therapy, since it is often deregulated in a wide range of tumor types (10) (11) (12) . Normally, PI3K-AKT signaling plays an important role in cell survival, proliferation, growth and motility. Several PI3K-AKT-associated molecules such as growth factors (e.g., IGF-1, VEGF, EGF or PDGFα) and related receptors are frequently dysregulated in GEP-NETs (13) . Thus, targeting growth factor receptors and the related downstream AKT-pathway has become a rationale for innovative medical treatment of GEP-NETs. This led to clinical studies exploring the effect of targeted drugs such as bevacizumab or sunitinib (14, 15) . Recently, it was shown that the mTOR-inhibitor everolimus significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events (16) .
Activated PI3K leads to the recruitment of the serinethreonine protein kinase AKT to the plasma membrane, where it is phosphorylated at residues Thr308 and Ser473 by the phosphoinositide-dependent protein kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2) (17, 18) . Three isoforms of AKT are known, of which the relative importance of each seems to be cell type-specific (19) . The most important inhibitor of AKT-signaling is PTEN (phosphatase and tensin homolog deleted on chromosome 10). PTEN is the second most commonly mutated tumor suppressor gene in cancer (20) . Tumors with mutated PTEN are more likely to be resistant against currently used targeted therapies, e.g., the HER2/neu-antibody trastuzumab (21, 22) . Targeting the PI3K-AKT-pathway directly might be an especially effective approach in PTEN-mutated cancer (23, 24) .
GEP-NETs often have increased levels of activated, phosphorylated AKT (p-AKT) and show loss of expression of PTEN (13, (25) (26) (27) (28) . Furthermore, for patients with gastrointestinal neuroendocrine tumors, increased pAKT and pAKT: PTEN expression ratios have been shown to be predictive for survival (29) .
Several drugs targeting AKT have been developed by now. One of them is the selective small molecule inhibitor triciribine, which inhibits all three isoforms of AKT (30) . While for other tumor entities there are already phase I studies on the way (31, 32) , the efficacy of an AKT-inhibitor for anti-neoplastic treatment in GEP-NETs has not yet been evaluated.
We therefore examined the potency of triciribine in three distinct neuroendocrine gastrointestinal tumor cell lines with different growth characteristics. We investigated triciribineinduced growth inhibition, induction of apoptosis, and effects on a broad range of cancer-associated gene products. We also looked for additive anti-neoplastic effects of triciribine when combined with conventional cytostatic drugs or other targeted drugs, affecting different molecules of the PI3K-AKT-pathway.
Materials and methods
Cell culture. The human pancreatic BON cell line, established from a human pancreatic carcinoid tumor (33) and the cholecystokinin secreting murine neuroendocrine cell line STC-1 (34) were grown in a 1:1 mixture of DMEM and Ham's F-12 medium containing 10% (v/v) FCS (Biochrom Co., Berlin, Germany) and 1% (v/v) L-glutamine. The human insulinoma cell line CM (35) , provided by Professor P. Pozzilli (University La Sapienza of Rome, Italy), was cultured in RPMI-1640 supplemented with 10% (v/v) FCS (Biochrom) and 1% L-glutamine. All cell lines were kept at 37˚C in a humidified atmosphere (5% CO 2 ).
Drugs. Triciribine was purchased from Merck, Darmstadt, Germany. Doxorubicin and 5-fluorouracil (5-FU) were purchased from Sigma (St. Louis, MO, USA). NVP-AEW541 was from Cayman Chemicals (Ann Harbor, MI, USA) and RAD-001 was purchased from Biomol GmbH (Hamburg, Germany). Stock solutions were prepared in DMSO and stored at -20˚C; they were diluted to the final concentration in fresh media before each experiment. In all experiments, the final DMSO concentration was <0.1%.
Impedance-based real-time cell proliferation analysis. Cell viability and proliferation was assessed with the xCELLigence real-time cell analysis system (Roche Molecular Diagnostics, Mannheim, Germany). CM cells (10,000) and BON cells (20,000) were seeded on 96-well E-plates and cell attachment, spreading and proliferation were initially monitored every 15 min for 24 h. After treatment, measurement intervals were 1 min for 12 h and then continuously every 15 min for further 55 h. Cell proliferation was recorded as arbitrary units (cell index) defined as (R n -R b )/15Ω with R n being the impedance at time point n and R b being the background impedance of wells containing complete growth medium only.
Measurement of growth inhibition. Drug-induced changes in cell numbers of BON, STC-1 and CM cells were evaluated by crystal violet staining, as described (36) . In brief, cells in 96-well plates were fixed with 1% glutaraldehyde. Then, cells were stained with 0.1% (w/v) crystal violet. The unbound dye was removed by washing with water. Bound crystal violet was solubilized with 0.2% Triton X-100. Light extinction, which increases linearly with the cell number, was analyzed at 570 nm using an ELISA-Reader. Potential synergy between triciribine and doxorubicin, 5-FU, RAD-001 or NVP-AEW541 was calculated using the method of Chou and Talalay with Calcusyn software (Biosoft, Ferguson, MO, USA) (37) . All proliferation assays were performed in triplicate.
Determination of cytotoxicity. Cells were seeded at a density of 4,000 cells/well into 96-well microtitre plates and incubated with rising concentrations of triciribine for 8-24 h. Thereafter, the release of the cytoplasmic enzyme lactate dehydrogenase (LDH), indicating unspecific cytotoxicity, was determined by using a colorimetric kit from Roche as described elsewhere (38) . Maximum release of LDH was obtained by adding 100 µl 2% (v/v) Triton X-100 to untreated cells. For determinations, 100 µl of each sample were incubated with 100 µl LDH assay reagent for 10 min at room temperature in the dark. The absorbance of samples was measured at 490 nm. Percentage of LDH release was determined by dividing released LDH of the cells by maximum LDH release multiplied by 100.
Western blotting. Western blotting was performed as described (39, 40) . In brief, whole-cell extracts were prepared by lysing cells. Lysates containing 30 µg protein were subjected to gel electrophoresis. Proteins were then transferred to PVDF membranes by electroblotting for 1.5 h. Blots were blocked in 5% skim milk powder solution (Merck) for 1 h, and incubated at 4˚C overnight with antibodies directed against AKT, pAKT and PTEN (1:1,000; Cell Signaling, MA, USA) as well as with anti-human cyclin D1 (1:2,000; Santa Cruz Biotechnology, CA, USA). After incubation with horseradish peroxidase-coupled anti-IgG antibodies (1:10,000; Amersham, Uppsala, Sweden) at room temperature for at least 1 h, the blot was developed using enhanced chemiluminescent (ECL) detection (Amersham) and subsequently exposed to Hyperfilm ECL film (Amersham) for 0.5-10 min. Experiments were performed three times, and representative experiments are shown.
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Concentration and purity were measured by absorption spectrophotometry (GeneQuant, Biochrom, Cambridge, UK) at 260 and 280 nm. The cDNA was synthesized from 2 µg of total RNA using the Superscript RT kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The sequences of PTEN primer pair were: PTEN (forward, 5'-CCAATGTTCAGTGGCGGAACT-3'; reverse, 5'-GAACTT GTCTTCCCGTCGTGTG-3') (41). Reverse transcriptase-PCR was carried out in a total volume of 50 µl containing 200 nmol/l of each primer, 200 µmol/l dNTPs (Invitrogen), 1.5 mM MgCl 2 and 2 U aTaq DNA-polymerase (Promega, Madison, WI, USA). The PCR was performed in a Peltier thermal cycler (PTC-200, MJ-Research, USA) with the primers described above.
DNA microarray (84 cancer pathway-specific genes). Total cellular RNA was extracted from cells using ArrayGrade Total RNA Isolation Kit (SABiosciences, Frederick, MD, USA). RNA was quantified by spectrophotometer (GeneQuant, Biochrom). The True-Labelling AMP 2.0 amplification kit (SABiosciences) was used for transcription of mRNA into cDNA, which was then converted into biotin-labelled cRNA using biotin-16-UTP (Roche) via in vitro transcription. Before hybridization, the cRNA probes were purified with an ArrayGrade cRNA cleanup kit (SABiosciences). The purified cRNA probes were then hybridized to the pre-treated Oligo GEArray Human Cancer Pathway Finder array (OHS-033, SABiosciences). After washing steps, array spots binding cRNA were detected by the chemiluminescence method according to the manufacturer's procedure. Image acquisition was performed using X-ray film and digital scanner. Spots were analysed and converted to numerical data by using the GEArray Expression Analysis Suite software (SABiosciences). Data evaluation included background correction (subtraction of minimum value) and normalization to reference genes. The cut-off for up-regulation was set at a 1.4-fold increase of the ratio of genes in the treated samples, whereas down-regulation was determined as the 0.8-fold expression of genes in the treated samples.
Migration assay. CM cells were allowed to grow into full confluence in 6-well plates. The monolayer was then scratched with a 10-µl pipette tip. Fresh growth medium was added and different concentrations of triciribine were added. Images were taken with Kappa digital camera after 24 h of incubation at 37˚C in a humidified atmosphere of 5% CO 2 . The migrated cells were quantified by using the software TScratch (42) .
Annexin V-FITC assay. Apoptosis was monitored by detection of Annexin V expression on the outer leaflet of the cell membrane, which is an early event in the apoptotic cascade, using the apoptosis detection kit (Pharmingen, CA, USA). Briefly, the cells grown on slides were treated with different concentrations of triciribine and 48 h later were washed with PBS. Then the cells were incubated for 30 min at 22-25˚C with FITC-conjugated Annexin V incubation reagent [containing 1 µg/ml Annexin V-biotin and 2 µmol/l ethidium bromide (EB)]. After washing again with PBS, cells were examined using fluorescence microscopy. Cells negative for both EB and Annexin V staining were defined as living and healthy cells; EB-negative but Annexin V-positive staining cells reflected early apoptotic cells, while cells positive for both EB and Annexin V were regarded as secondary necrotic cells (initially apoptotic and then necrotic) (43, 44) .
Cell cycle analysis/apoptotic cell death by flow cytometry. Cell cycle analysis was performed by a modified method of Fried et al (45) . Cells were seeded at a concentration of 10 5 cells/ml and treated with triciribine for 24 h. Cells were then washed with PBS and fixed in PBS/2% (vol/vol) formaldehyde on ice for 30 min. Afterwards cells were incubated in ethanol/PBS (2:1 vol/vol) for 30 min and pelleted. Resuspension in PBS containing 40 µg/ml RNase A followed. After incubation for 30 min at 37˚C, cells were pelleted again and resuspended in PBS containing 50 µg/ml propidium iodide. Cells were then analyzed on a FACSCalibur flow cytometer using CellQuestPro Software (BD Biosciences, Heidelberg, Germany) and FlowJo Software (Tree star, Ashland, OR). Apoptotic cells can be identified as a hypoploid cell population commonly called 'subG1' (46) .
Chick chorioallantoic membrane (CAM) angiogenesis assay.
CAM assay was done as described previously (47) . Briefly, 2.5x10 6 CM cells were resuspended in 20 µl growth medium and mixed with 30 µl growth factor reduced Matrigel (BD Biosciences). The cell suspensions were implanted on the CAM on day 10 of chick embryo development. After two days, tumors were formed and topically treated once with 20 µM triciribine in 100 µl PBS. The control group was treated with PBS. Tumor growth and viability of the embryo were controlled daily for 72 h by stereo microscopy. At the end of experiments, tumors were recovered and pictures were taken using a stereomicroscope equipped with a Kappa digital camera system.
Results
Triciribine-mediated growth inhibition. In this study, we explored the anti-tumor activity of AKT inhibition by monitoring cell response to triciribine in gastroenteropancreatic neuroendocrine tumor cells, using a real-time cell analysis system (xCELLigence). This system continuously monitors live cells in response to the exposure of triciribine and provides kinetic information from the cell population. The normalized cell index (CI) is an arbitrary unit derived from electrical impedance measurement and correlates with cell viability. Dose-and time-dependent cell responses to triciribine were clearly shown in tumor cell line CM (Fig. 1A) , whereas no appreciable cell response was observed in the cell line BON (Fig. 1B) . To confirm these effects, changes in cell number caused by triciribine were additionally studied by crystal violet assays. In serum-containing medium, triciribine time-and dose-dependently inhibited the growth of fast growing CM cells (doubling time 21±1 h). After 96 h of incubation with 0-20 µmol/l triciribine, a decrease in cell number of >65% was observed (Fig. 1C) . However, in moderate growing BON cells (doubling time 34±4 h), there was no growth inhibition at doses as high as 50 µmol/l, and only a meager inhibition of about 18% at very high doses of 75 µmol/l triciribine after 48 h. This initial effect wore off to 7% after 96 h (Fig. 1D) . Treatment of STC-1 cells, representing a slow growing neuroendocrine gastrointestinal tumor cell line (doubling time 54±6 h), led to a growth inhibition of >55% (Fig. 1E) .
Cytotoxic effects of triciribine. Non-specific cytotoxicity was evaluated by cellular LDH release into the culture medium. Incubating CM cells with 0-20 µmol/l for up to 24 h did not result in a significant increase in LDH release, indicating that triciribine does not directly affect cell membrane integrity and does not have immediate toxic effects even at concentrations, which led to pronounced growth inhibitory effects. Similar results were obtained with STC-1 cells. Expectedly, no cytotoxic effect of triciribine was observed in the non-responding BON cells either (data not shown).
Triciribine inhibited phosphorylation of AKT and cyclin D1 in gastrointestinal neuroendocrine tumor cells. The three cells lines were treated with triciribine (0-20 µmol/l) for 48 h. As a marker of AKT activation, we measured phosphorylation of AKT at serine 473. In CM-and STC-1 cells, levels of p-AKT were dose-dependently decreased. The cell cycle regulator cyclin D1 is known to be up-regulated by p-AKT. We therefore looked for changes in cyclin D1 levels in triciribine treated GEP-NET cells. Proportionally to changes in activated AKT, there was also a dose-dependent decrease in cyclin D1 in CM-and STC-1 cells ( Fig. 2A and B) . Interestingly, also in BON cells a dose-dependent decrease in phosphorylated-AKT was observed, but in contrast to CM and STC-1 cells an associated decrease in cyclin D1 expression did not occur (Fig. 2C) .
AKT inhibition changed the expression of various cancerassociated genes. Effects of triciribine treatment on the expression of cancer-associated genes were investigated by performing a cancer pathway gene array (Table I) . CM cells were treated with 20 µmol/l triciribine for 48 h and alterations in gene expression was compared to untreated control cells, yielding a marked regulation of 48 genes.
Cell cycle arrest-related genes. Cyclin E and cyclin-dependent kinase 2 (CDK2), important for the G1/S-phase transition, are down-regulated after triciribine treatment. CDK4, which is influencing the G0/S-phase transition, was also down-regulated. The CDK inhibitors p21, p27 as well as p16, inhibitors of G0/ S-phase transition, were up-regulated. Triciribine treatment also led to a down-regulation of E2F transcription factor 1 (E2F1), a regulator of the expression of several proteins involved in cell cycle progression.
Apoptosis and senescence-related genes. V-akt was downregulated and PTEN the main inhibitor of AKT was up-regulated. Moreover, other apoptosis inducing genes, such as APAF1 and BAX were up-regulated and the anti-apoptotic gene BIRC5 (survivin) was down-regulated. Surprisingly, the expression of PIK3R1, which is an important inhibitor of PI3K and a potential oncogene, was also down-regulated. Proapoptotic effects of triciribine. To further investigate the role of apoptosis in the observed anti-neoplastic effects of triciribine, we analyzed cell membrane binding to Annexin V, which serves as a marker of early apoptosis. After 48 h of incubation with 0-20 µmol/l of triciribine a dose-dependent increase in apoptosis-specific Annexin V staining became apparent. Albeit to a small degree only, there were also additional signs of late apoptosis as indicated by the simultaneous staining of cells with propidium iodide (data not shown). Moreover, flow cytometry revealed a moderate induction of apoptosis after 48 h in cells treated with triciribine as indicated by the 'subG1' cell population. At 20 µmol/l triciribine the amount of apoptotic cells increased about 3-fold (data not shown). Together with the above-described changes in the expression pattern of several pro-apoptotic and anti-apoptotic genes (Table I) the data suggest that the anti-neoplastic effects of triciribine in GEP-NET cells are at least partially due to an induction of apoptosis.
AKT inhibition and cell cycle arrest. Since the PI3K-AKTpathway is known to modulate the cell cycle leading to cell cycle progression, we investigated the effect of triciribine on the cell cycle of GEP-NET cells using flow cytometry. Triciribine led to a dose-dependent increase in the G0/G1-phase while the amount of cells in S-and G2/M-phase decreased, indicating cell cycle arrest (Fig. 3) . Together with the above-mentioned downregulation of several cell cycle-promoting genes (Table I) , we could clearly demonstrate that also an induction of cell cycle contributes to the anti-neoplastic mode of action of triciribine in GEP-NET cells.
Correlation of PTEN and efficacy of triciribine. To check out the possible correlation of growth inhibition and the expression of PTEN in the different GEP-NET cell lines, RT-PCR was performed (Fig. 4) . While triciribine-sensitive CM cells showed the lowest expression of PTEN, the PTEN expression in triciribine insensitive BON cells was very pronounced. Respective Western blots revealed a cell line-specific expression of PTEN, which was not altered by triciribine treatment (data not shown). Our data confirm the notion that PTEN expression markedly influences the sensitivity of GEP-NET cells to triciribine treatment. Changes in migration induced by triciribine. Scratch assays were used to examine the effect of triciribine on neuroendocrine tumor cell migration. CM cells were treated with increasing doses of triciribine for 24 h, which markedly decreased the migration of GEP-NET cells as compared to the untreated control cells (Fig. 5 ). Analysis of signal intensity of each gene and global normalization was performed with GEArray Expression Analysis Suite. We compared gene expression in untreated and triciribine treated CM cells. The ratio describes the magnitude of changes in gene expression after triciribine treatment.
As a cut-off we chose ratio values of higher than 1.4 for up-regulated genes and lower than 0.8 for down-regulated genes. Of the 113 analyzed genes known to be cancer associated, 28 genes were up-regulated and 20 genes were down-regulated. Triciribine inhibits in vivo tumor growth as assessed by the chicken CAM assay. The anti-neoplastic effect of triciribine on GEP-NET growth was additionally evaluated in vivo. Therefore, CM cells were inoculated into the chicken chorioallantoic membrane of 10-day-old chick embryos. The inoculated CM cells formed macroscopic tumors in each case. After 3 days of incubation with triciribine (20 µmol/l) either macroscopically evaluation (Fig. 6A) or mathematical calculation of tumor volumes (Fig. 6B) revealed that triciribine markedly inhibited GEP-NET tumor growth >50%, as compared to the untreated control tumors.
Anti-neoplastic potency of triciribine in combination with other drugs. To look for possible additive or even synergistic effects of combination treatment of GEP-NET cells with triciribine, we used cytostatic drugs, which are already established for medical treatment of GEP-NETs. CM-and STC-1 cells were treated with 5 µmol/l triciribine as well as increasing doses of either doxorubicin or 5-FU. When given as a single drug both 5-FU and doxorubin led to dose-dependent growth inhibition of CM and STC-1 cells (Fig. 7) . Results of combination treatment of the drugs together with triciribine were analyzed with Calcusyn software. Triciribine synergistically enhanced the anti-proliferative effect of doxorubicin, although this was only slightly pronounced. On the other hand combinations of triciribine and 5-FU were at least moderately synergistic (Table II) .
Additional combinations of triciribine together with an mTORC1 inhibitor (RAD-001), or an IGF-1R inhibitor (NVP-AEW541) were also investigated (Fig. 8) . Both combinations were strongly synergistic in both CM and STC-1 cells. The combination of NVP-AEW541 and triciribine showed the strongest synergism of all the tested combinations (Table II) .
Discussion
Due to the use of established drugs such as somatostatin analogues, great progress has been made in controlling the often debilitating hypersecretion syndrome encountered in patients with metastasized GEP-NETs (48). However, current cytostatic therapy regimens aiming at slowing tumor progression or even inducing remission are so far of only limited success (6,7). The PI3K-AKT-pathway is known to be important in tumor survival and progression when deregulated (10) (11) (12) . Furthermore, GEP-NETs often show an overly active AKT and PTEN mutations, the most important suppressor protein of the PI3K-AKT-pathway (26) (27) (28) (29) . There are some publications looking at the effect of pharmacologic inhibition of PI3K in carcinoid cells as well as inhibiting the isozyme AKT1 using siRNA in vitro (49, 50) . However, the observed effects were only moderate and high doses of inhibitors had to be employed. Furthermore, the observations were restricted to single cell line experiments. So far, there are no publications looking at the effects of pharmacologically inhibiting AKT in neuroendocrine tumor cell lines.
In this study, we showed that inhibition of all three isoforms of AKT by triciribine may become a promising approach for novel treatment options in GEP-NETs. By using the impedance based measurement of cell proliferation we could show that the pan-AKT inhibitor triciribine (30) led to a time-and dose-dependent reduction in cell growth of GEP-NET cells.
The normalized CI is an arbitrary unit derived from electrical impedance measurement and correlates with the cell viability (51) . The growth inhibitory activity results from an induction of the cell cycle and/or apoptosis. At least in CM and STC-1 cells the anti-proliferative effects correlated with the reduction in protein levels of phosphorylated AKT and one of its CI <0.9 denotes slight synergistic effects of two agents, <0.7 synergistic effects, <0.3 strong synergistic effects. CI 0.9-1.1 denotes an additive relationship. CI >1.1 denotes antagonism. Synergy was assessed using the method of Chou et al (37) with Calcusyn software. Proliferation assays were performed in triplicate. The data are derived from a representative experiment; studies were performed three times. Fa, fraction of cells affected by treatment; CI, combination index. regulated proteins, the cell cycle promoter cyclin D1 (52, 53) . Since GEP-NETs are very heterogeneous and differ from slow growing to fast growing aggressive tumors (1), it is important to look at different representatives of this tumor entity when testing new therapeutic agents. We therefore chose three cell lines with different growth rates and origins: human insulinoma CM cells are the fastest growing cells in our study with a doubling time of 21 h; human pancreatic carcinoid BON cells (doubling time 34 h); and slow growing cholecystokinin-secreting tumor cells of the gut (STC-1 cells) with a doubling time of 54 h (54).
The fastest and the slowest growing cell lines CM and STC-1 responded very similarly to triciribine. The IC 50 values for CM cells were 12.7±1.2 µmol/l and even as low as 7.1±0.8 µmol/l in STC-1 cells. On the other hand moderately fast growing BON cells showed only low sensitivity to triciribine. Marked growth inhibitory effects of triciribine were not observed below doses of as much as 75 µmol/l. In vitro concentrations of up to 20 µmol/l triciribine which later could potentially be translated into in vivo studies, did not induce appreciable effects on AKT phosphorylation of BON cells, while in the other two GEP-NET models 'in vivo-like' concentrations led to a strong inhibition of AKT-activity. In other tumor entities there was a clear correlation between baseline levels of p-AKT and sensitivity to AKT inhibitors (30, 55) . In our case, the most sensitive cell line STC-1, also showed the highest level of baseline AKT phosphorylation, while insensitive BON cells showed the lowest baseline activity of AKT. So, at least partially the observed differences in baseline AKT activity can help to explain the differences in sensitivity to triciribine treatment, while no correlation between doubling time and responsiveness could be observed.
The CAM assay was used to examine the effect of triciribine on GEP-NET cell growth in vivo, which has not been investigated so far. Triciribine treated and tumor bearing CAM showed a significant decrease in tumor volume as compared to untreated controls, indicating substantial activity also in vivo. Moreover, no toxic effects were observed in chicken CAMs at the dose tested during the assay, confirming the good tolerability of the compound.
Employing cancer gene expression profiling we could show that the anti-neoplastic effects of triciribine were partially caused by an induction of cell cycle arrest. Several genes responsible for cell cycle control were altered by triciribine treatment. For instance, cyclin E and CDK2, both being responsible for enhancing the G1/S-phase transition in cells, were downregulated after triciribine treatment. Cyclin D1 was decreased in the immunoblots, as well as the gene expression of the closely interacting CDK4, indicating a G0/S-phase arrest. The association between down-regulation of AKT activity and cyclin D1 expression as well as the importance of AKT-induced cyclin D1 expression as a key mediator of carcinogenic transformation has already been shown (56, 57) . Moreover, the cyclin-dependent kinase inhibitors p21, p27 and p16 known to influence cell cycle regulation were up-regulated after triciribine treatment. Finally, E2F1, which inhibits the expression of several proteins involved in cell cycle progression, was down-regulated by triciribine, hereby adding to the effect of cell cycle arrest (58) . Correspondingly flow cytometry revealed an accumulation of events in G0/G1-phase while the amount of cells in S-transition or G2/M-phase was decreased.
Induction of apoptosis by triciribine was confirmed by flow cytometry, which revealed an increase in the apoptosis-specific subG1-peak and respective changes in the expression pattern of apoptosis associated genes were observed in the gene arrays. Down-regulation of V-AKT and up-regulation of its main inhibitor PTEN both suggest an apoptosis inducing effect, since normally an activated AKT is strongly anti-apoptotic. Other apoptosis inducing gene products were also up-regulated, including APAF1 and BAX, complementing the down-regulation of anti-apoptotic genes like BIRC5 (survivin). Our findings are in line with those of Hu et al who showed that inhibition of Akt results in a re-expression of p16, which in turn leads to the down-regulation of anti-apoptotic survivin in hepatocellular carcinoma cells (59) .
Changes in the expression pattern of PTEN are known to be one of the most common alterations in cancer cells (20) . Thus, we performed RT-PCR, looking at levels of PTEN expression in the different GEP-NET models, as this might offer an explanation for the observed differences in triciribine sensitivity of the different GEP-NET models. PTEN levels are higher in BON cells than in CM cells and also, although to a much lesser degree, higher than in STC-1 cells. Given these results, only part of the differences among cell lines in terms of sensitivity to triciribine can be explained. PTEN could cause the differences between BON and CM cells. However, PTEN levels among BON and STC-1 cells are nearly identical, although STC-1 cells are far more sensitive to triciribine treatment.
There are a number of possible additional explanations for the observed effects. PTEN could be mutated in STC-1 cells, leading to a mal-functioning protein, as is the case in many other known cancers (20) . Recently, it has been shown, that PI3K has important effects independent of AKT (60), maybe being more pronounced in BON cells. However, a work of Pitt et al investigating the effect of a direct PI3K inhibitor on BON cells led to different results (50) . In accordance with our results, it was shown that only very high doses of the PI3K inhibitor were successful in inhibiting the growth of BON cells, thus making it unlikely that AKT-independent effects of PI3K are responsible for the observed resistance of BON cells.
Monotherapy is often not successful at inducing complete remission in cancer. In our case, combination treatment is especially suggestive, since inhibition of AKT has been shown to facilitate induction of apoptosis by other drugs (55) . Furthermore, in our study monotherapy with triciribine led to a maximum proliferation reduction of about 60%. Earlier phase I/II studies already indicated that at higher doses triciribine exhibits therapy-limiting adverse reactions (61) , emphasizing the idea to use triciribine as a drug for combination treatment, as its synergistic effects are promising, while the monotherapeutic efficacy appears to be rather limited. Thus, we used the already established cytostatic drugs doxorubicin or 5-FU in combination with triciribine. Both drugs were synergistic with triciribine, although more pronounced with 5-FU than with doxorubicin in CM and STC-1 cells.
Next we looked at possible combinations of triciribine together with other targeted cancer therapeutics. The protein mTORC1 is part of the PI3K-AKT-pathway and closely interacts with AKT (62) . Moreover, AKT activity is known to determine sensitivity to mTOR inhibitors by regulating cyclin D1 (63, 64) . Recently, a large multicenter trial was published, showing that the mTOR-inhibitor everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors (16) . Studies showing that mTORC1 inhibition leads to up-regulation of AKT via loss of feedback inhibition (65) make mTORC1 inhibitors even more attractive as combination partners for triciribine. As a consequence, currently several new compounds are being studied as dual PI3K/mTOR inhibitors (66, 67) .
When we combined triciribine with the mTORC1 inhibitor, everolimus (RAD-001), we found synergistic anti-proliferative effects, similar to those seen in combinations of triciribine together with 5-FU, although certainly not as strong as the effects seen with triciribine and an IGF-1R inhibitor. One possible explanation could be the finding by Sarbassov et al that prolonged exposure of cells to an mTOR inhibitor finally also leads to an inhibition of mTORC2, thus eventually inhibiting AKT (62) . In this respect Jiao et al recently demonstrated that a subset of pancreatic neuroendocrine tumors exhibits genetic alterations of the mTOR pathway. The authors concluded that the mutational status of genes coding for proteins in the mTOR pathway will help to predict clinical response to mTOR inhibition and thus could potentially be used to stratify patients for treatment with mTOR inhibitors (68) .
The cancer pathway-specific gene array used in our investigation gave another hint for promising combination therapy. Expression of IGF-1 was >3.5-fold elevated in triciribine treated cells. Additional evaluation of IGF-1R expression by qRT-PCR exhibited a concomitant up-regulation of IGF-1R of ~20%, as compared to untreated controls (data not shown). Up-regulation of the IGF-1/IGF-1R system may be interpreted as a kind of mitogenic escape mechanism of neuroendocrine tumor cells to compensate for the triciribine-induced inhibition of AKT-signaling (69) . Thus, we hypothesized that additional inhibition of IGF-1/IGF-1R system may help in increasing anti-neoplastic effects of triciribine treatment. Indeed, when triciribine was used together with the IGF-1R tyrosine kinase inhibitor NVP-AEW541, there were highly synergistic effects in CM and STC-1 cells, more pronounced than in any of the other tested combinations. Currently, there is a phase II study in progress, looking at the efficacy of an IGF-1R monoclonal antibody in gastrointestinal neuroendocrine tumors (70) . If the results of the study turn out to be positive, we suggest that a combination of triciribine with an IGF-R1 inhibitor for GEP-NETs would be very promising.
In conclusion, we were able to show that AKT inhibition is an attractive target in GEP-NETs. However, the low sensitivity of BON cells indicates that careful selection of appropriate candidates for therapy with an AKT inhibitor is required. Initial screening for PTEN status and activity of AKT in a given GEP-NET might help in taking the appropriate decision. Combination treatments in our study showed promising synergistic effects, thus making AKT inhibition an especially attractive way to increase efficacy of other chemotherapeutic drugs.
